In this week’s New England Journal of Medicine (NEJM), there is an interesting article entitled, “Contingent knowledge and looping effects — a 66-year-old man with PSA-detected prostate cancer and regrets”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "looping", context, contingent, data, interpretation, knowledge | 7 Comments »
Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, data, interpretation, outcome, statin | 1 Comment »
Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: aggressive, data, genetic, genomic, predict, risk, testing | 2 Comments »
Over the weekend, an interesting article on clinical trials appeared (somewhat unexpectedly) in the New York Times color supplement. … READ MORE …
Filed under: Uncategorized | Tagged: astrology, clinical, data, dredging, trial | 1 Comment »
It has been a couple of weeks now since Vice President Biden started work on the cancer “moon shot” initiative that President Obama announced during the State of the Union speech to Congress on January 12. … READ MORE …
Filed under: Uncategorized | Tagged: cancer, data, efficiency, moon shot | 3 Comments »
Patient registries are potentially a rich source of information with which to evaluate outcomes. They often include patient characteristics, details of the therapies they received, and outcomes tracked over time. They also provide full population data of all patients treated at participating centers, and can provide very large amounts of data over time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: data, poutcome, radiation, registry, SBRT, therapy | Leave a comment »
On April 29 this year, the National Cancer Institute (NCI) announced a decision to eliminate all PSA data from their current data files because of apparent inaccuracies in the ways that such data had been accumulated over time and administered. The full ramifications of this are — as yet — unclear. … READ MORE …
Filed under: Uncategorized | Tagged: data, Medicare, National Cancer Institute, PSA, SEER | Leave a comment »
At the annual meeting of the American Urological Association (AUA) this morning, Dr. Matt Cooperberg reported that a total of 450 US-based urologists had now signed up to contribute data on their prostate cancer patients to the AQUA Registry. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: AQUA, care, data, patterns, registry | 6 Comments »
According to media reports this morning, a number of payer organizations in the USA are initiating new policies regarding the coverage of proton beam radiation therapy (PBRT) for the treatment of localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: beam, cost, data, PBRT, proton, radiation | 13 Comments »
As we move near to the annual meeting of the American Society of Clinical Oncology (ASCO) — which will start at the end of May in Chicago — ASCO has been making a lot of noise about its prototype CancerLinQ™ network. Just how valuable this will be for the future management of prostate cancer will take a while to work out. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CancerLinQ, clinical, data, Management, outcomes, practise | 4 Comments »
There has clearly been a good deal of interest in the data on ARN-509 reported at the recent meeting of the European Society of Medical Oncology (ESMO) … at least from the investment community. … READ MORE …
Filed under: Drugs in development | Tagged: ARN-509, data, trial | Leave a comment »
There’s an interesting opinion piece on the Medscape web site today by Professor Eric Topol of the Scripps Translational Science Institute in La Jolla, California. His subject is “Consumer-driven healthcare makes docs uncomfortable.” … READ MORE …
Filed under: Uncategorized | Tagged: data, health care, individualized, Topol | 3 Comments »
Dr. William Catalona has long been one of the strongest advocates of prostate cancer screening. He has been a key individual in the development and promotion of PSA testing for some 20 years, and he believes passionately that prostate cancer screening saves lives. We respect his beliefs and his right to express those beliefs. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: data, manipulation, mortality | 15 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 